Therapeutic efficacy of a 177Lu-abeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 3, 2007, Pages 333-341

  Miao, Yubin ^a   Shelton, Tiffani ^b   Quinn, Thomas P ^b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

177Lu labeled peptide; Melanoma; Targeted radionuclide therapy; melanocyte stimulating hormone

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177 ALPHA INTERMEDIN[11 ARGININE] RE 188; ALPHA INTERMEDIN DERIVATIVE; AMMONIUM ACETATE; LUTETIUM 177; PLACEBO; RHENIUM 188; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ALPHA INTERMEDIN; ARGININE; CHELATING AGENT; LUTETIUM; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG CONJUGATION; DRUG EFFICACY; DRUG SYNTHESIS; ISOTOPE LABELING; MELANOMA; MELANOMA B16; MOUSE; NEPHROTOXICITY; NONHUMAN; PH; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; ANIMAL; DISEASE MODEL; DRUG EFFECT; KIDNEY; PATHOLOGY; RADIATION EXPOSURE; RADIOGRAPHY; SURVIVAL;

ALPHA-MSH; ANIMALS; ARGININE; CHELATING AGENTS; DISEASE MODELS, ANIMAL; HETEROCYCLIC COMPOUNDS, 1-RING; KIDNEY; LUTETIUM; MELANOMA; MICE; RADIOISOTOPES; SURVIVAL ANALYSIS;

EID: 85047696907     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.376.A     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622.
3. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 2000;7:971.
4. Otte A, Jermann E, Behe M, et al. A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792.
5. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417.
6. Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with Y-DOTA-dPhe-Tyr-octreotide: The experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32:141.
7. 3-octreotide. Eur J Nucl Med 2001;28:426.
8. 90Y-DOTATOC. J Nucl Med 2002;43:610.
9. DeJong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Pre-clinical and clinical findings. Semin Nucl Med 2002; 32:133.
10. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628.
11. 3]octreotate in a rat liver micrometastases model. Int J Cancer 2003;104:376.
12. Hruby VJ, Sharma SD, Toth K, et al. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann NY Acad Sci 1993;680:51.
13. Tatro JB, Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinology 1987;121:1900.
14. Siegrist W, Solca F, Stutz S, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989;49:6352.
15. Tatro JB, Wen Z, Entwistle ML, et al. Interaction on an α-melanocyte stimulating hormone-diptheria toxin fusion protein with melanotropin receptors in human metastases. Cancer Res 1992;52:2545.
16. 7]α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980;77:5754.
17. Bard DR, Knight CG, Page-Thomas DP. A chelateing derivative of a-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer 1990;62:919.
18. 111In-DTPA-labeled analogs for alpha-melanocyte-stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo. Int J Cancer 1994;58:749.
19. Wraight EP, Bard DR, Maughan CG, et al. The use of a chelating derivative of alpha-melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 1992;65:112.
20. 7]-α-MSH, an α-melanocyte stimulating hormone analog. Nucl Med Biol 1997;24:171.
21. Froidevaux S, Calame-Christe M, Tanner H, et al. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 2002;43:1699.
22. Froidevaux S, Calame-Christe M, Schuhmacher J, et al. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for imaging of melanoma metastases. J Nucl Med 2004;45:116.
23. Giblin MF, Wang NN, Hoffman TJ, et al. Design and charaterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 1998;95:12814.
24. 99mTechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues. Cancer Res 2000;60:5649.
25. 188Re-labeled alpha-melanocyte-stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 2002;101:480.
26. Miao Y, Whitener D, Feng W, et al. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconj Chem 2003;14:1177.
27. 188Re-labeled α-melanocyte-stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med 2005;46:121.
28. Miao Y, Hylarides M, Fisher DR, et al. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res 2005;11:5616.
29. 177Lu-labeled alpha-melanocyte-stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 2005;32:485.
30. 177Lu-labeled alpha-melanocyte-stimulat-ing hormone peptide analogues. Nucl Med Biol 2006; 33:723.
31. 177Lu radionuclides. Cancer Biother Radiopharm 2005;20:436.
32. Zalutsky M, Bigner D. Radioimmunotherapy with α-particle-emitting radioimmunoconjugates. Acta Oncol 1996;35:373.
33. 3-octreotate. J Nucl Med 2005;46: 83S.
34. 90Y-DOTATOC. J Nucl Med 2005;46:1310.
35. Anderson CJ, Jones LA, Bass LA, et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med 1998;39:1944.
36. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999;5:3608.